| 28 | 0 | 37 |
| 下载次数 | 被引频次 | 阅读次数 |
寡转移性非小细胞肺癌（NSCLC）是一种介于局限性疾病与广泛转移之间的中间状态，其诊断依赖于精准的影像学技术。局部治疗在寡转移性NSCLC中显示出显著的生存获益，尤其是与系统治疗联合时。不同寡转移部位的治疗策略各有特点，需结合病灶特点和患者个体化选择。尽管多项Ⅱ期研究支持局部治疗的价值，但最佳适用人群、治疗模式、应用时机及与新型药物的联合仍需前瞻性的Ⅲ期临床试验验证。文章就寡转移性NSCLC患者治疗的相关研究进行梳理，列举了正在进行的临床试验，以确定未来研究方向，并改善此类患者的预后。
Abstract：Oligometastatic non-small cell lung cancer(NSCLC) represents an intermediate state between localized disease and widespread metastasis, with its diagnosis relying on precise imaging techniques. Local therapy has demonstrated significant survival benefits in oligometastatic NSCLC, particularly when combined with systemic treatment. Treatment strategies for different oligometastatic sites vary depending on lesion characteristics and individualized patient selection. Although multiple phase Ⅱ studies support the value of local therapy, the optimal patient population, treatment modalities, timing of intervention, and combination with novel drugs still require validation through prospective phase Ⅲ trials. Here, we review relevant articles on the management of oligometastatic NSCLC patients and highlight ongoing clinical trials to identify future research directions and improve the care of this patient population.
[1]Herbst RS,Morgensztern D,Boshoff C,et al.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454.DOI:10.1038/nature25183.
[2]Zappa C,Mousa SA.Non-small cell lung cancer:current treatment and future advances[J].Transl Lung Cancer Res,2016,5(3):288-300.DOI:10.21037/tlcr.2016.06.07.
[3]Morgensztern D,Ng SH,Gao F,et al.Trends in stage distribution for patients with non-small cell lung cancer:a National Cancer Database survey[J].J Thorac Oncol,2010,5(1):29-33.DOI:10.1097/JTO.0b013e3181c5920c.
[4]Hellman S,Weichselbaum RR.Oligometastases[J].JClin Oncol,1995,13(1):8-10.DOI:10.1200/JCO.1995.13.1.8.
[5]Iyengar P,All S,Berry MF,et al.Treatment of oligometastatic non-small cell lung cancer:an ASTRO/ESTRO clinical practice guideline[J].Pract Radiat Oncol,2023,13(5):393-412.DOI:10.1016/j.prro.2023.04.004.
[6]范文文，仲佳，白桦，等.肺癌免疫治疗精准化策略中的多模态影像组学与人工智能协同研究进展[J].中国肿瘤临床与康复，2025,32(4):219-228.DOI:10.13455/j.cnki.cjcor.113494-20250227-0080.
[7]Downey RJ,Ng KK,Kris MG et al.A phaseⅡtrial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis[J].Lung Cancer,2002,38(2):193-7.DOI:10.1016/s0169-5002(02)00183-6.
[8]Lopez Guerra JL,Gomez D,Zhuang Y,et al.Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis[J].Int J Radiat Oncol Biol Phys,2012,84(1):e61-7.DOI:10.1016/j.ijrobp.2012.02.054.
[9]Dingemans AC,Hendriks LEL,Berghmans T,et al.Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report[J].J Thorac Oncol,2019,14(12):2109-2119.DOI:10.1016/j.jtho.2019.07.025.
[10]Guckenberger M,Lievens Y,Bouma AB,et al.Characterisation and classification of oligometastatic disease:a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation[J].Lancet Oncol,2020,21(1):e18-e28.DOI:10.1016/S1470-2045(19)30718-1.
[11]Brand?o M,Durieux V,Berghmans T,et al.Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review[J].Transl Lung Cancer Res,2021,10(7):3473-3485.DOI:10.21037/tlcr-20-964.
[12]Gomez DR,Blumenschein GR Jr,Lee JJ,et al.Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-smallcell lung cancer without progression after first-line systemic therapy:a multicentre,randomised,controlled,phase 2 study[J].Lancet Oncol,2016,17(12):1672-1682.DOI:10.1016/S1470-2045(16)30532-0.
[13]Gomez DR,Tang C,Zhang J,et al.Local consolidative therapy vs.maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer:long-term results of a multi-institutional,phaseⅡ，randomized study[J].J Clin Oncol,2019,37(18):1558-1565.DOI:10.1200/JCO.19.00201.
[14]Iyengar P,Wardak Z,Gerber DE,et al.Consolidative radiotherapy for limited metastatic non-small-cell lung cancer:a phase 2 randomized clinical trial[J].JAMAOncol,2018,4(1):e173501.DOI:10.1001/jamaoncol.2017.3501.
[15]Palma DA,Olson R,Harrow S,et al.Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET):a randomised,phase 2,open-label trial[J].Lancet,2019,393(10185):2051-2058.DOI:10.1016/S0140-6736(18)32487-5.
[16]Wang XS,Bai YF,Verma V,et al.Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer[J].J Natl Cancer Inst,2023,115(6):742-748.DOI:10.1093/jnci/djac015.
[17]Qiwen Li,H Ma,R Zheng,et al.65P-Durvalumabcombined with chemotherapy and radiotherapy in patients with oligometastaticnon-small cell lung cancer (SABRcure)[J].Ann Oncol,2024,9(suppl_3):1-53.DOI:10.1016/esmoop/esmoop102569.
[18]Iyengar P,Hu C,Gomez DR,et al.NRG-LU002:Randomized phaseⅡ/Ⅲtrial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic nonsmall cell lung cancer (NSCLC)[J].J Clin Oncol,2024,42:8506.DOI:10.1200/JCO.2024.42.16_suppl.8506.
[19]Ashworth AB,Senan S,Palma DA,et al.An individual patient data metanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer[J],Clin Lung Cancer,2014,15(5):346-355.DOI:10.1016/j.cllc.2014.04.003.
[20]Mordant P,Arame A,De Dominicis F,et al.Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer?[J].Eur J Cardiothorac Surg,2012,41(3):617-622.DOI:10.1093/ejcts/ezr042.
[21]Galluzzi L,Aryankalayil MJ,Coleman CN,et al.Emerging evidence for adapting radiotherapy to immunotherapy[J].Nat Rev Clin Oncol,2023,20(8):543-557.DOI:10.1038/s41571-023-00782-x.
[22]Zhao B,Li H,Ma W.Durvalumab after chemoradiotherapy for patients with unresectable stageⅢNSCLC:the PACIFIC-R study[J].J Thorac Oncol,2023,18(4):e38-e39.DOI:10.1016/j.jtho.2022.11.002.
[23]朱以香，王洁.肺癌脑转移的药物治疗进展[J].中国肿瘤临床与康复，2024,31(7):397-406.DOI:10.13455/j.cnki.cjcor.113494-2024-2024-0122.
[24]Gaspar LE,Prabhu RS,Hdeib A,et al.Congress of neurological surgeons systematic review and evidencebased guidelines on the role of whole brain radiation therapy in adults with newly diagnosed metastatic brain tumors[J].Neurosurgery,2019,84(3):E159-E162.DOI:10.1093/neuros/nyy541.
[25]Graber JJ,Cobbs CS,Olson JJ.Congress of neurological surgeons systematic review and evidence-based guidelines on the use of stereotactic radiosurgery in the treatment of adults with metastatic brain tumors[J].Neurosurgery,2019,84(3):E168-E170.DOI:10.1093/neuros/nyy543.
[26]Gondi V,Bauman G,Bradfield L,et al.Radiation therapy for brain metastases:an ASTRO clinicalpractice guideline[J].Pract Radiat Oncol,2022,12(4):265-282.DOI:10.1016/i.prro.2022.02.003.
[27]Mercier O,Fadel E,de Perrot M,et al.Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer[J].J Thorac Cardiovasc Surg,2005,130(1):136-140.DOI:10.1016/j.jtcvs.2004.09.020.
[28]Luketich JD,Burt ME.Does resection of adrenal metastases from non-small cell lung cancer improve survival?[J].Ann Thorac Surg,1996,62(6):1614-1616.DOI:10.1016/s0003-4975(96)00611-x.
[29]Solaini L,Ministrini S,Tomasoni M,et al.Adrenalectomy for metastasis:long-term results and predictors of survival.Endocrine[J],2015,50(1):187-92.DOI:10.1007/s12020-015-0596-8.Epub 2015 Apr 12.
[30]K?nig L,H?fner,MF,Katayama S,et al.Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients[J].Radiat Oncol,2020,15(1):30.DOI:10.1186/s13014-020-1480-0.
[31]Botsa EI,Thanou IL,Papatheodoropoulou AT,et al.Thermal ablation in the management of adrenal metastasis originating from non-small cell lung cancer:a 5-year single-center experience[J].Chin Med J (Engl),2017,130(17):2027-2032.DOI:10.4103/0366-6999.210496.
[32]Takahashi Y,Adachi H,Mizukami Y,et al.Patient outcomes post-pulmonary resection for synchronous bonemetastatic non-small cell lung cancer[J].J Thorac Dis,2019,11(9):3836-3845.DOI:10.21037/jtd.2019.09.17.
[33]Hishida T,Yoshida J,Aokage K,et al.Postoperative oligo-recurrence of non-small-cell lung cancer:clinical features and survival[J].Eur J Cardiothorac Surg,2016,49(3):847-853.DOI 10.1093/ejcts/ezv249.
[34]Girard N,Deshpande C,Lau C,et al.Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases[J].Am J Surg Pathol,2009 Dec;33(12):1752-1764.DOI:10.1097/PAS.0b013e3181b8cf03.
[35]De Leyn P,Moons J,Vansteenkiste J,et al.Survival after resection of synchronous bilateral lung cancer[J].Eur J Cardiothorac Surg,2008,34(6):1215-1222.DOI:10.1016/j.ejcts.2008.07.069.Epub 2008 Oct 1.
[36]Filippi AR,Badellino S,Guarneri A,et al.Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases[J].Technol Cancer Res Treat,2014,13(1):37-45.DOI:10.7785/tcrt.2012.500355.Epub2013 Jun 24.
[37]Londero F,Grossi W,Morelli A,et al.Surgery versus stereotactic radiotherapy for treatment of pulmonary metastases.a systematic review of literature[J].Future Sci OA,2020,6(5):FSO471.DOI:10.2144/fsoa-2019-0120.
[38]Churilla TM,Chowdhury IH,Handorf E,et al.Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection:a secondary analysis of a randomized clinical trial[J].JAMA Oncol,2019,5(2):243-247.DOI:10.1001/jamaoncol.2018.4610.
[39]Lewis SL,Porceddu S,Nakamura N,et al.Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases:an international survey of>1000radiation oncologists[J].Am J Clin Oncol,2017,40(4):418-422.DOI:10.1097/COC.0000000000000169.
[40]Lodeweges JE,Klinkenberg TJ,Ubbels JF,et al.Longterm outcome of surgery or stereotactic radiotherapy for lung oligometastases[J].J Thorac Oncol,2017,12(9):1442-1445.DOI:10.1016/j.jtho.2017.05.015.
[41]T?nnies M,Pfannschmidt J,Bauer TT,et al.Metastasectomy for synchronous solitary non-small cell lung cancer metastases[J].Ann Thorac Surg,2014,98(1):249-256.DOI:10.1016/j.athoracsur.2014.03.028.
[42]Collaud S,Stahel R,Inci I,et al.Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage.Lung Cancer[J],2012,78(3):234-238.DOI:10.1016/j.lungcan.2012.09.011.
[43]Lencioni R,Crocetti L,Cioni R,et al.Response to radiofrequency ablation of pulmonary tumours:a prospective,intention-to-treat,multicentre clinical trial(the RAPTURE study)[J].Lancet Oncol,2008,9(7):621-628.DOI:10.1016/S1470-2045(08)70155-4.
[44]Hasegawa T,Yamakado K,Nakatsuka A,et al.Unresectable adrenal metastases:clinical outcomes of radiofrequency ablation[J].Radiology,2015,277(2):584-593.DOI:10.1148/radiol.2015142029.
[45]Tsai CJ,Yang JT,Shaverdian N,et al.Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block[CURB]oligoprogression):an open-label,randomised,controlled,phase 2 study[J].Lancet,2024,403(10422):171-182.DOI:10.1016/S0140-6736(23)01857-3.
[46]Mavrikios A,Remon J,Quevrin C,et al.Local control strategies for management of NSCLC with oligoprogressive disease[J].Cancer Treat Rev,2023,120:102621.DOI:10.1016/j.ctrv.2023.102621.
[47]Zhang J,Gao J,Jiang S,et al.Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer:incidence,pattern of failure,and clinical value of local consolidative therapy.Cancer Immunol Immunother[J],2024,73(8):140.DOI:10.1007/s00262-024-03720-7.
基本信息:
DOI：10.13455/j.cnki.cjcor.113494-20250517-0211
中图分类号:R734.2
引用信息:
[1]隰成林,商琰红.寡转移性非小细胞肺癌的治疗进展[J].中国肿瘤临床与康复,2025,32(11):692-700.DOI:10.13455/j.cnki.cjcor.113494-20250517-0211.